Suchergebnisse - "Perrot, Aurore"

PubPharm (147)

1

RAS/RAFlandscape in monoclonal plasma cell conditions

enthalten in: Blood | 2024

von Schavgoulidze, A. | Corre, J. | Samur, M. | +24

2

Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

enthalten in: Advances in therapy | 2024

von Einsele, H. | Moreau, P. | Bahlis, N. | +23

3

An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd) : SELECT study

enthalten in: Leukemia & lymphoma | 2024

von Perrot, A. | Delimpasi, S. | Spanoudakis, E. | +8

4

Inflamed Natural Killer cells with adhesion defects are associated with a poor prognosis in Multiple Myeloma

enthalten in: bioRxiv.org | 2024

von Blanquart, E. | Ekren, R. | Rigaud, B. | +15

5

Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies : a national retrospective study on the behalf of G2I and Intergroupe Francophone du Myélome

enthalten in: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases | 2024

von Jourdes, A. | Cellerin, E. | Touzeau, C. | +31

6

Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

enthalten in: Advances in therapy | 2024

von Einsele, H. | Moreau, P. | Bahlis, N. | +23

7

Daratumumab Carfilzomib Lenalidomide and Dexamethasone with tandem transplant in high-risk newly diagnosed myeloma

enthalten in: Blood | 2024

von Touzeau, C. | Perrot, A. | Hulin, C. | +13

8

Real-life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access : The CARMYN study

enthalten in: EJHaem | 2024

von Laribi, K. | Leleu, X. | Texier, N. | +16

9

Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

enthalten in: Advances in therapy | 2024

von Moreau, P. | Mateos, M. | Gonzalez Garcia, M. | +26

10

Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma : final overall survival analysis

enthalten in: Haematologica | 2024

von Richardson, P. | Perrot, A. | Miguel, J. | +15

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[15]